Clinical Updates in Cystic Fibrosis:
Advances in CFTR Modulator Therapy
for Improved Patient Outcomes
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education
credits from this archive.
This activity is valid from January 10, 2018 to January 31, 2019
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
an educational grant from
Cystic fibrosis (CF) is a genetic, autosomal recessive disorder
caused by the presence of mutations in both copies of the gene for
the protein cystic fibrosis transmembrane conductance regulator (CFTR).
Cystic Fibrosis mostly affects mostly the lungs but also the
pancreas, liver, kidneys and intestine. Common symptoms include
difficulty breathing, sinus infections, poor growth, fatty stool,
clubbing of the finger and toes, and infertility in males among
others. There is no cure for cystic fibrosis, but recent treatment
breakthroughs are available for about half of CF patients who have
two copies of the F508del mutation in their CFTR gene. This new CFTR
modulation therapeutic focuses on counteracting the damage caused by
the disease, enabling patients to breath more easily and stay out of
the hospital, improving outcomes and quality of life. This option is
a major breakthrough in CF management, because it is the first
therapy that specifically targets an important genetic mutation.
Upon Completion of this
activity, participants will be able to:
Discuss the details of real-world
outcomes for cystic fibrosis patients treated with CFTR-based
Examine approved and emerging CFTR-based
therapeutic options in terms of efficacy, safety, and clinical
potential to improve pulmonary and non-pulmonary outcomes of
patients with cystic fibrosis
Apply the principles of early
diagnosis and early pharmaco-therapeutic intervention to the
cystic fibrosis pediatric population
Explore current challenges with
medication and treatment adherence in the cystic fibrosis
Analyze new data related to emerging
combination CFTR modulator therapies in cystic fibrosis
||Elliot C. Dasenbrook, MD
Cleveland Clinic Respiratory Institute
Director, Cleveland Clinic Adult Cystic Fibrosis Center
Dasenbrook has no relevant financial relationships to
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education for
NAMCP designates this enduring material for a maximum of 1 AMA PRA
Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
supported by an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue